Boehringer Ingelheim launches the First Approved Treatment for Idiopathic Pulmonary Fibrosis in Algeria
Nintedanib is the only treatment for Idiopathic Pulmonary Fibrosis approved by the Algerian Ministry of Health
Search
World Heart Day 2021
Cardiovascular diseases, including heart disease, are the leading cause of death and disability worldwide and are closely linked to kidney and metabolic diseases.
Boehringer Ingelheim Brings Hundreds of Leading Cardiologists from Eight Countries Together
Boehringer Ingelheim Brings Hundreds of Leading Cardiologists from Eight Countries Together
Regional experts highlight need for coordinated, collaborative efforts in stroke care through
Regional experts highlight need for coordinated, collaborative efforts in stroke care through dedicated hospital unitsRegional experts highlight need for coordinated, collaborative efforts in stroke care through dedicated hospital units
Scleroderma Life Hacks
Video series featuring people living with scleroderma using everyday items in different ways to help them manage their symptoms. Part of the global 'More Than Scleroderma' initiative developed by Boehringer Ingelheim, with support from patient organi
Giving Life a Chance
The Angels initiative honours stroke units and the everyday heroes making a difference for stroke patients
Boehringer Ingelheim commences local production of first batch of antihypertensive medicines
Boehringer Ingelheim commences local production of first batch of antihypertensive medicines in Algeria
Boehringer Ingelheim unites dermatologists to discuss the management of Generalized Pustular Psoriasis (GPP)
The ‘GPP Summit, discussed latest research and advances in the management of GPP to help improve patient outcomes across Saudi Arabia, and the United Arab Emirates.
EURORDIS Award
EURORDIS has selected Boehringer Ingelheim for the first time as recipient of the prestigious Black Pearl Award 2020
Bridging the gap in Generalized Pustular Psoriasis (GPP)
Emmanuelle Clerisme-Beaty, Head of Clinical Development and Medical Affairs, Dermatology, discusses recently published insights from GPP patients.
Elevating Cardio-Renal-Metabolic Care: Boehringer Ingelheim Imparts Latest Insights to 400 Regional Experts
Boehringer Ingelheim hosted the ‘CRM Summit’ to facilitate exchanges and discussions on the latest advances in the management of cardiovascular, renal, and metabolic diseases to help improve patient outcomes across India, the Middle East and Africa
Boehringer Ingelheim Convenes Educational Meetings to Empower Over 300 Regional Experts with Latest Heart Failure Advances
• Boehringer Ingelheim hosted ‘Heart Talks’and ‘MEDEX’ to discuss latest updates in heart failure management and help improve patient outcomes across India, the Middle East and Africa
Mechanistic Modeling in Biotherapeutic Drug Development
Mechanistic modeling is revolutionizing biotherapeutic drug development with the goal of getting new medicines to patients faster, more reliably and more cost-effectively.
Combination Therapy
We are designing smart combinations of immuno-oncology and cancer cell directed therapies to maximise the benefit to our patients.
Micardis®
Treatment of hypertension. For the reduction of the risk of myocardial infarction (heart attack), stroke or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take A
Boehringer Ingelheim announces Reach Africa Access Healthcare programs outcomes
Boehringer Ingelheim, announces “In Reach Africa” Access to Healthcare programs outcomes
COPD Patient brochure
Clinical Collaborations
Clinical Collaborations
Research Collaborations
Research Collaborations
Translational Medicine in Immunology
Find out how translational medicine is helping bring transformational therapies to patients
Spotlight on GPP
Emmanuelle Clerisme-Beaty, Head of Clinical Development and Medical Affairs, Dermatology, answers some frequently asked questions about GPP.
The UAE MOHAP Approves the First and Only Therapy for the Treatment of Adult Generalized Pustular Psoriasis Flares
The first treatment of its kind in the UAE by Boehringer Ingelheim is the only FDA and EMA-approved medication used to treat GPP flares in adult patients and works to help block a source of inflammation that may cause GPP flares
sustainably fighting rabies info hub
Did you know that every nine minutes, rabies takes a human life? Find out how we support the elimination of this deadly disease.
Partnering Vanderbilt WCNDD
Boehringer Ingelheim and the Warren Center for Neuroscience Drug Discovery are partnering to find new medicines for patients with neuropsychiatric disorders.
What are acute exacerbations in IPF?
Risk factors for acute exacerbations in IPF are unclear, but there is evidence that a number of factors may increase risk. Learn more here.